LLY vs HSIC
By Alex · Tickerpine
Eli Lilly and Company vs Henry Schein, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | HSIC |
|---|---|---|
| Price | $1,443.50 | $86.22 |
| Market cap | $1.29T | $9.53B |
| P/E ratio | 46.9 | 23.6 |
| ROE | 86.02% | 9.20% |
| Profit margin | 31.90% | 3.07% |
| Revenue growth | 38.60% | 4.00% |
| Dividend yield | 0.48% | 0.00% |
| Beta | 0.39 | 0.86 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs HSIC in plain English
- LLY is the bigger company — about 134.9× the market cap of HSIC.
- HSIC is cheaper on earnings (P/E 23.6 vs 46.9).
- LLY earns a higher return on equity (86% vs 9%).
- LLY is growing revenue faster (39% vs 4%).
- LLY pays a dividend (0.48%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
HSIC return calculator
See what $1,000 in Henry Schein, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.